Heron Research Development vs Total Revenue Analysis

HRTX Stock

USD 1.60 0.09 5.33%

Heron Therapeuti financial indicator trend analysis is much more than just examining Heron Therapeuti latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Heron Therapeuti is a good investment. Please check the relationship between Heron Therapeuti Research Development and its Total Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.

Research Development vs Total Revenue

Research Development vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Heron Therapeuti Research Development account and Total Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Heron Therapeuti's Research Development and Total Revenue is 0.54. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Heron Therapeuti, assuming nothing else is changed. The correlation between historical values of Heron Therapeuti's Research Development and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Heron Therapeuti are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Research Development i.e., Heron Therapeuti's Research Development and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Research Development

Total Revenue

Total revenue comprises all receipts Heron Therapeuti generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Heron Therapeuti's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Heron Therapeuti current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.At this time, Heron Therapeuti's Selling General Administrative is fairly stable compared to the past year. Discontinued Operations is likely to rise to about 1.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 28.3 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	258.2M	227.5M	172.6M	181.2M
Cost Of Revenue	46.0M	54.9M	65.1M	68.4M

Total Operating Expenses Cost Of Revenue

Heron Therapeuti fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Inventory	Other Current Assets	Accounts Payable	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		0.23	0.89	0.86	0.78	0.76	0.07	-0.65	0.28	0.66	0.23	0.91	0.78	0.64	0.0	0.77	0.5	0.66	1.0	0.41	0.71	0.71	0.35	-0.09	-0.06	-0.7
Short Long Term Debt Total	0.23		0.56	0.48	-0.42	0.62	0.91	-0.86	-0.23	0.77	0.87	-0.15	0.64	0.85	0.93	0.77	0.95	0.77	0.15	0.05	0.77	0.19	-0.09	0.0	0.22	-0.52
Other Current Liab	0.89	0.56		0.96	0.44	0.9	0.38	-0.89	0.17	0.84	0.46	0.65	0.91	0.88	0.31	0.95	0.79	0.87	0.85	0.48	0.89	0.73	0.25	-0.09	0.03	-0.81
Total Current Liabilities	0.86	0.48	0.96		0.46	0.78	0.25	-0.81	0.32	0.72	0.36	0.66	0.9	0.81	0.18	0.88	0.73	0.75	0.84	0.68	0.8	0.65	0.46	-0.12	-0.03	-0.8
Total Stockholder Equity	0.78	-0.42	0.44	0.46		0.31	-0.51	-0.04	0.39	0.13	-0.32	0.95	0.29	0.04	-0.57	0.21	-0.15	0.11	0.83	0.28	0.16	0.52	0.34	-0.07	-0.19	-0.31
Property Plant And Equipment Net	0.76	0.62	0.9	0.78	0.31		0.46	-0.88	0.11	0.97	0.6	0.49	0.75	0.84	0.44	0.91	0.78	0.94	0.7	0.24	0.9	0.84	-0.14	-0.02	0.09	-0.75
Net Debt	0.07	0.91	0.38	0.25	-0.51	0.46		-0.7	-0.61	0.6	0.77	-0.29	0.51	0.7	0.89	0.6	0.81	0.63	0.0	-0.26	0.65	0.0	-0.2	0.05	0.27	-0.37
Retained Earnings	-0.65	-0.86	-0.89	-0.81	-0.04	-0.88	-0.7		0.0	-0.92	-0.74	-0.3	-0.88	-0.98	-0.7	-0.98	-0.97	-0.94	-0.58	-0.29	-0.95	-0.56	-0.06	0.03	-0.15	0.72
Cash	0.28	-0.23	0.17	0.32	0.39	0.11	-0.61	0.0		0.04	-0.14	0.39	0.03	-0.02	-0.32	0.06	-0.09	-0.01	0.3	0.71	-0.06	0.37	0.3	-0.12	-0.21	-0.11
Non Current Assets Total	0.66	0.77	0.84	0.72	0.13	0.97	0.6	-0.92	0.04		0.79	0.34	0.74	0.86	0.61	0.91	0.87	0.92	0.59	0.18	0.93	0.74	-0.15	0.01	0.13	-0.73
Non Currrent Assets Other	0.23	0.87	0.46	0.36	-0.32	0.6	0.77	-0.74	-0.14	0.79		-0.1	0.49	0.67	0.84	0.66	0.81	0.62	0.15	-0.03	0.75	0.28	-0.14	0.06	0.18	-0.47
Cash And Short Term Investments	0.91	-0.15	0.65	0.66	0.95	0.49	-0.29	-0.3	0.39	0.34	-0.1		0.5	0.3	-0.35	0.46	0.13	0.33	0.94	0.38	0.37	0.58	0.42	-0.11	-0.17	-0.46
Net Receivables	0.78	0.64	0.91	0.9	0.29	0.75	0.51	-0.88	0.03	0.74	0.49	0.5		0.9	0.41	0.91	0.83	0.81	0.75	0.44	0.89	0.46	0.39	-0.04	0.13	-0.83
Common Stock Shares Outstanding	0.64	0.85	0.88	0.81	0.04	0.84	0.7	-0.98	-0.02	0.86	0.67	0.3	0.9		0.69	0.98	0.96	0.94	0.59	0.28	0.91	0.49	0.08	-0.07	0.15	-0.7
Non Current Liabilities Total	0.0	0.93	0.31	0.18	-0.57	0.44	0.89	-0.7	-0.32	0.61	0.84	-0.35	0.41	0.69		0.58	0.79	0.61	-0.08	-0.21	0.59	0.01	-0.29	0.11	0.33	-0.22
Other Stockholder Equity	0.77	0.77	0.95	0.88	0.21	0.91	0.6	-0.98	0.06	0.91	0.66	0.46	0.91	0.98	0.58		0.92	0.94	0.71	0.33	0.95	0.63	0.11	-0.05	0.12	-0.75
Total Liab	0.5	0.95	0.79	0.73	-0.15	0.78	0.81	-0.97	-0.09	0.87	0.81	0.13	0.83	0.96	0.79	0.92		0.88	0.43	0.25	0.9	0.4	0.08	-0.04	0.17	-0.69
Property Plant And Equipment Gross	0.66	0.77	0.87	0.75	0.11	0.94	0.63	-0.94	-0.01	0.92	0.62	0.33	0.81	0.94	0.61	0.94	0.88		0.59	0.19	0.89	0.65	-0.16	-0.01	0.18	-0.73
Total Current Assets	1.0	0.15	0.85	0.84	0.83	0.7	0.0	-0.58	0.3	0.59	0.15	0.94	0.75	0.59	-0.08	0.71	0.43	0.59		0.42	0.64	0.67	0.4	-0.09	-0.08	-0.67
Short Term Debt	0.41	0.05	0.48	0.68	0.28	0.24	-0.26	-0.29	0.71	0.18	-0.03	0.38	0.44	0.28	-0.21	0.33	0.25	0.19	0.42		0.21	0.31	0.62	-0.13	-0.14	-0.48
Inventory	0.71	0.77	0.89	0.8	0.16	0.9	0.65	-0.95	-0.06	0.93	0.75	0.37	0.89	0.91	0.59	0.95	0.9	0.89	0.64	0.21		0.64	0.08	0.01	0.15	-0.77
Other Current Assets	0.71	0.19	0.73	0.65	0.52	0.84	0.0	-0.56	0.37	0.74	0.28	0.58	0.46	0.49	0.01	0.63	0.4	0.65	0.67	0.31	0.64		-0.11	-0.01	-0.04	-0.54
Accounts Payable	0.35	-0.09	0.25	0.46	0.34	-0.14	-0.2	-0.06	0.3	-0.15	-0.14	0.42	0.39	0.08	-0.29	0.11	0.08	-0.16	0.4	0.62	0.08	-0.11		-0.17	-0.2	-0.25
Common Stock Total Equity	-0.09	0.0	-0.09	-0.12	-0.07	-0.02	0.05	0.03	-0.12	0.01	0.06	-0.11	-0.04	-0.07	0.11	-0.05	-0.04	-0.01	-0.09	-0.13	0.01	-0.01	-0.17		0.95	0.16
Common Stock	-0.06	0.22	0.03	-0.03	-0.19	0.09	0.27	-0.15	-0.21	0.13	0.18	-0.17	0.13	0.15	0.33	0.12	0.17	0.18	-0.08	-0.14	0.15	-0.04	-0.2	0.95		0.05
Other Liab	-0.7	-0.52	-0.81	-0.8	-0.31	-0.75	-0.37	0.72	-0.11	-0.73	-0.47	-0.46	-0.83	-0.7	-0.22	-0.75	-0.69	-0.73	-0.67	-0.48	-0.77	-0.54	-0.25	0.16	0.05

Click cells to compare fundamentals

Heron Therapeuti Account Relationship Matchups

Heron Therapeuti fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	512.8M	353.6M	305.7M	251.0M	222.5M	233.6M
Short Long Term Debt Total	19.8M	24.6M	159.5M	157.5M	179.6M	188.6M
Other Current Liab	86.4M	88.9M	62.4M	73.7M	70.3M	73.8M
Total Current Liabilities	96.7M	102.5M	71.1M	82.4M	79.7M	83.7M
Total Stockholder Equity	403.8M	236.5M	77.6M	13.6M	(34.0M)	(32.3M)
Property Plant And Equipment Net	33.4M	39.0M	33.6M	29.8M	25.6M	26.9M
Net Debt	(52.1M)	(80.5M)	69.0M	142.1M	151.0M	158.5M
Retained Earnings	(1.2B)	(1.4B)	(1.6B)	(1.8B)	(1.9B)	(1.8B)
Cash	71.9M	105.1M	90.5M	15.4M	28.7M	27.8M
Non Current Assets Total	33.7M	39.4M	51.3M	45.5M	33.7M	35.4M
Cash And Short Term Investments	391.0M	208.5M	157.6M	84.9M	80.4M	60.9M
Net Receivables	39.9M	41.9M	35.5M	52.0M	60.1M	63.1M
Common Stock Shares Outstanding	81.8M	90.8M	98.5M	108.9M	138.1M	145.0M
Liabilities And Stockholders Equity	512.8M	353.6M	305.7M	251.0M	222.5M	233.6M
Non Current Liabilities Total	12.2M	14.6M	157.1M	155.0M	176.8M	185.6M
Other Stockholder Equity	1.6B	1.6B	1.7B	1.8B	1.9B	2.0B
Total Liab	108.9M	117.1M	228.1M	237.4M	256.5M	269.3M
Property Plant And Equipment Gross	33.4M	39.0M	33.6M	29.8M	42.6M	44.8M
Total Current Assets	479.1M	314.2M	254.4M	205.4M	188.8M	198.2M
Accumulated Other Comprehensive Income	85K	257K	(6K)	(19K)	13K	13.7K
Short Term Debt	7.6M	13.0M	4.8M	5.4M	6.2M	4.0M
Inventory	25.0M	41.9M	48.4M	54.6M	42.1M	44.2M
Other Current Assets	23.2M	43.9M	25.9M	14.0M	6.1M	5.5M
Accounts Payable	2.8M	525K	3.8M	3.2M	3.2M	3.2M
Common Stock Total Equity	782K	903K	913K	1.0M	1.2M	658.0K
Common Stock	903K	913K	1.0M	1.2M	1.5M	1.6M
Other Assets	346K	16.6M	17.7M	15.7M	18.1M	19.0M
Short Term Investments	319.1M	103.4M	67.0M	69.5M	51.7M	55.8M
Property Plant Equipment	19.6M	22.7M	33.6M	29.8M	34.3M	36.0M
Net Tangible Assets	403.8M	236.5M	77.6M	13.6M	15.6M	14.8M
Retained Earnings Total Equity	(960.7M)	(1.2B)	(1.4B)	(1.6B)	(1.5B)	(1.4B)
Capital Surpluse	1.3B	1.6B	1.6B	1.7B	1.9B	2.0B
Short Long Term Debt	28.7M	4.6M	5.6M	7.1M	8.1M	8.3M
Net Invested Capital	409.5M	243.5M	226.7M	162.9M	139.8M	196.2M
Net Working Capital	382.4M	211.7M	183.4M	123.1M	109.1M	170.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Heron Stock Analysis

When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Heron Research Development vs Total Revenue Analysis

Research Development vs Total Revenue

Research Development vs Total Revenue Correlation Analysis

Correlation Coefficient

Research Development

Total Revenue

Heron Therapeuti fundamental ratios Correlations

Heron Therapeuti Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Heron Therapeuti fundamental ratios Accounts

Also Currently Popular

Additional Tools for Heron Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Total Current Liabilities	+ 0.96	Other Current Liab
Total Liab	+ 0.96	Common Stock Shares Outstanding
Total Liab	+ 0.95	Short Long Term Debt Total

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Inventory	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Non Current Assets Total	- 0.92	Retained Earnings